ATE548390T1 - Verfahren zur induktion von autolyse in infektiösen bakterien - Google Patents

Verfahren zur induktion von autolyse in infektiösen bakterien

Info

Publication number
ATE548390T1
ATE548390T1 AT05729289T AT05729289T ATE548390T1 AT E548390 T1 ATE548390 T1 AT E548390T1 AT 05729289 T AT05729289 T AT 05729289T AT 05729289 T AT05729289 T AT 05729289T AT E548390 T1 ATE548390 T1 AT E548390T1
Authority
AT
Austria
Prior art keywords
infection
treatment
bacteria
infectious bacteria
autolysis
Prior art date
Application number
AT05729289T
Other languages
English (en)
Inventor
Keith Alan Charlton
Andrew Justin Radcliffe Porter
Ian Broadbent
Original Assignee
Haptogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haptogen Ltd filed Critical Haptogen Ltd
Application granted granted Critical
Publication of ATE548390T1 publication Critical patent/ATE548390T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT05729289T 2004-03-27 2005-03-24 Verfahren zur induktion von autolyse in infektiösen bakterien ATE548390T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0407008.2A GB0407008D0 (en) 2004-03-27 2004-03-27 Methods for inducing rapid cell death (autolysis) in infectious bacteria
PCT/GB2005/001108 WO2005094883A2 (en) 2004-03-27 2005-03-24 Methods for inducing autolysis in infectious bacteria

Publications (1)

Publication Number Publication Date
ATE548390T1 true ATE548390T1 (de) 2012-03-15

Family

ID=32188889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05729289T ATE548390T1 (de) 2004-03-27 2005-03-24 Verfahren zur induktion von autolyse in infektiösen bakterien

Country Status (15)

Country Link
US (3) US20070218058A1 (de)
EP (2) EP1730197B1 (de)
JP (2) JP5167466B2 (de)
KR (2) KR20130001741A (de)
CN (1) CN1934134B (de)
AT (1) ATE548390T1 (de)
AU (1) AU2005227666B2 (de)
CA (1) CA2558435A1 (de)
DK (1) DK1730197T3 (de)
ES (1) ES2381374T3 (de)
GB (1) GB0407008D0 (de)
HK (1) HK1099316A1 (de)
NO (1) NO20063871L (de)
SG (1) SG151316A1 (de)
WO (1) WO2005094883A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110124375A (ko) * 2002-08-13 2011-11-16 햅토젠 리미티드 항-락톤 또는 락톤 유도된 시그널 분자 항체를 이용한 감염성 세균 질환의 치료 방법
GB0407008D0 (en) * 2004-03-27 2004-04-28 Haptogen Ltd Methods for inducing rapid cell death (autolysis) in infectious bacteria
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
JP5170403B2 (ja) * 2008-03-14 2013-03-27 国立大学法人 筑波大学 細菌の増殖を制御する化合物及びその応用
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
EP3126333B1 (de) * 2014-04-03 2018-08-01 Helmholtz-Zentrum für Infektionsforschung GmbH Pqsr-modulatoren
CN108513984B (zh) * 2018-04-14 2020-12-29 华南农业大学 Ahl分子作为化学农药杀菌增效剂在黄单胞杆菌引起的黑腐病防治中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6395282B1 (en) * 1998-04-16 2002-05-28 University Of Rochester Immunogenic conjugates of Gram-negative bacterial autoinducer molecules
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
US6309651B1 (en) 1998-11-25 2001-10-30 Mcw Research Foundation Method of and compositions for immunization with the pseudomonas V antigen
GB9924195D0 (en) 1999-10-13 1999-12-15 Univ Nottingham N-Acyl homoserine lactones for the treatment of cardiac tachyarrhythmias Ischaemic heart disease or congestive heart failure
GB0007588D0 (en) 2000-03-30 2000-05-17 Univ Nottingham N-Acyl homoserine lactones
US6703513B1 (en) * 2000-06-02 2004-03-09 K-Quay Enterprises Llc Production and use of derivatized homoserine lactones
KR20110124375A (ko) * 2002-08-13 2011-11-16 햅토젠 리미티드 항-락톤 또는 락톤 유도된 시그널 분자 항체를 이용한 감염성 세균 질환의 치료 방법
GB0407008D0 (en) * 2004-03-27 2004-04-28 Haptogen Ltd Methods for inducing rapid cell death (autolysis) in infectious bacteria

Also Published As

Publication number Publication date
JP2007530649A (ja) 2007-11-01
US20110027280A1 (en) 2011-02-03
CN1934134A (zh) 2007-03-21
EP2261260A2 (de) 2010-12-15
ES2381374T3 (es) 2012-05-25
HK1099316A1 (en) 2007-08-10
US20070218058A1 (en) 2007-09-20
US20130011400A1 (en) 2013-01-10
EP1730197B1 (de) 2012-03-07
JP5167466B2 (ja) 2013-03-21
CN1934134B (zh) 2012-01-11
AU2005227666B2 (en) 2011-09-01
CA2558435A1 (en) 2005-10-13
JP2013040191A (ja) 2013-02-28
KR20070050865A (ko) 2007-05-16
GB0407008D0 (en) 2004-04-28
WO2005094883A3 (en) 2006-01-12
KR20130001741A (ko) 2013-01-04
AU2005227666A1 (en) 2005-10-13
EP1730197A2 (de) 2006-12-13
EP2261260A3 (de) 2011-01-05
SG151316A1 (en) 2009-04-30
DK1730197T3 (da) 2012-06-25
NO20063871L (no) 2006-08-30
WO2005094883A2 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
Minden-Birkenmaier et al. Honey-based templates in wound healing and tissue engineering
Becker et al. The effect of captivity on the cutaneous bacterial community of the critically endangered Panamanian golden frog (Atelopus zeteki)
Carter et al. Therapeutic manuka honey: no longer so alternative
ATE548390T1 (de) Verfahren zur induktion von autolyse in infektiösen bakterien
Black et al. Current concepts regarding the effect of wound microbial ecology and biofilms on wound healing
Song et al. Sub-optimal treatment of bacterial biofilms
Rangel et al. Detrimental effect of ozone on pathogenic bacteria
Brun Expert forecast on emerging biological risks related to occupational safety and health
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
Arnold et al. Bacterial biofilms and periprosthetic infections
BRPI0518406A2 (pt) composiÇÕes tendo uma alta eficÁcia antiviral e antibacteriana
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE427116T1 (de) Behandlung von bakteriellen infektionen
Khokhar et al. Viricidal treatments for prevention of coronavirus infection
Santos et al. Virucidal activity of the antiseptic mouthwash and dental gel containing anionic phthalocyanine derivative: in vitro study
Campoccia et al. Tracing the origins of extracellular DNA in bacterial biofilms: story of death and predation to community benefit
Al-Dahmoshi et al. Molecular detection of some virulence traits among Pseudomonas aeruginosa isolates, Hilla-Iraq
DE502004011851D1 (de) Caspase 3, 8, 9 oder 10 Inhibitoren in Kombination mit MEK Inhibitoren zur Behandlung von Influenza
DE602004022689D1 (de) Verwendung probiotischer bakterien zur behandlung von infektionen
Stibich et al. The microbiological impact of pulsed xenon ultraviolet disinfection on resistant bacteria, bacterial spore and fungi and viruses
ATE428684T1 (de) Verwendung von bisaminen zur verstärkung der antimikrobiellen wirkung von wässrigen zusammensetzungen
Trizna et al. Improving the efficacy of antimicrobials against biofilm-embedded bacteria using bovine hyaluronidase azoximer (Longidaza®)
Melvin et al. Clinical potential of engineered cationic antimicrobial peptides against drug resistant biofilms
Yanik et al. An ınvestigation into the in-vitro effectiveness of electrolyzed water against various microorganisms
ATE371461T1 (de) Verwendung von extrakten aus wurzeln von pelargonium sidoides und/oder pelargonium reniforme